NEW YORK (GenomeWeb News) – Clinical Data said today that the biomarker it had previously associated with response to its depression drug candidate vilazodone did not replicate its earlier success in the firm's most recent phase III study of the drug.
The Newton, Mass.-based drug developer and pharmacogenomic test maker reported positive top-line results from the second of two phase III studies of vilazodone. Clinical Data said that the drug achieved statistically significant results on the primary and secondary endpoints related to major depressive disorder.
Though the biomarker did not meet its goal in the study, Clinical Data said that it would continue to evaluate other biomarker candidates. "While our lead biomarker of response to vilazodone did not replicate in this trial, it is one in a series of candidate biomarkers that we will continue to evaluate," Carol Reed, chief medical officer of Clinical Data, said in a statement.
Clinical Data said that it intends to submit the data from the most recent study to the US Food and Drug Administration in support of its marketing application of vilazodone by the end of this year.
In Tuesday afternoon trade on the Nasdaq, shares of Clinical Data were up around 3 percent at $14.48.